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ABSTRACT
The epithermal neutron beam model of the Finnish boron neutron capture therapy (BNCT)
facility (FiR 1) was created using the two-dimensional (2D) discrete ordinates transport
(DORT) code. The final design of the beam was achieved using the DORT model: the optimal
thickness of the neutron moderator and the length and the thickness of the bismuth collimator
of the beam were calculated. The final beam model was validated experimentally with
dosimetric measurements. The computed neutron beam spectrum was first verified with
activation measurements free in air. Suitable brain tissue substitutes for neutron capture
therapy (NCT) dosimetry were examined. The computed thermal neutron fluence [and gold
(Au) and manganese (Mn) activation reaction rates], the gamma dose and the fast neutron
dose distributions in the three tissue substitute (TS) phantoms were verified with activation
and pair ionisation chamber measurements. The simplified neutron-photon beam model for
the treatment planning system (TPS) was determined from the DORT model. The TPS beam
model was experimentally validated in the three TS phantoms. The beam model was
normalised to the Au activation measurements at the thermal neutron maximum in the PMMA
(polymethylmethacrylate) phantom, which gave a link to the monitor units. The planned
radiation dose in the TPS is given in monitor units. The experimentally verified beam model
was first applied in the computations of the dose plans of the dog brain and in the treatment
planning of glioblastoma multiforme (GBM) patients in the Finnish BNCT project.
The 2D cylinder symmetrical horizontal DORT model of the FiR 1 epithermal neutron beam
was observed to be an effective and reliable tool for examining the effects of different
geometrical structures (moderator, collimator) on neutron and photon spectra. Of the simple
phantom materials, PMMA was found to simulate the thermal neutron fluence at its maximum
in the brain tissue 3 percentage units closer than water in the collimated epithermal neutron
beam. However, water simulated the absorbed gamma dose in the brain tissue 12 percentage
units closer than PMMA. In addition, a brain tissue equivalent liquid was designed. Parallel
verification of the beam model in water, PMMA and the brain equivalent liquid confirmed
reliability of the NCT dose computation. The DORT beam model was sufficiently accurate
(intensity correction 5%) to use as a beam model in TPS. The beam model was normalised at
the thermal neutron maximum in the PMMA phantom with the Au activation measurements.
The use of the calculated Au activation reaction rate (variation 3%) for the normalisation was
found to be less independent of the energy grouping of cross sections than the calculated Mn
activation reaction rate (variation 13%).
The soft tissue, bone and air cavities need to be defined separately to create an accurate three-
dimensional (3D) head model of the target area for the BNCT treatment planning. The
accuracy of the beam model can be roughly estimated with in vivo dosimetry, which is
recommended for use at epithermal neutron facilities in accordance with new protocols. The
2total uncertainty of the computed total absorbed BNCT dose at the dose maximum in the brain
tissue was estimated to be 8% (1SD) without uncertainty in boron concentration. The
uncertainty of the computed NCT doses arises mostly from uncertainties in measured doses,
thus, the uncertainty of the computed doses can be enhanced significantly by developing
measurement techniques.
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A-150 Plastic substitute material for tissue
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scattering
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BNCT_Rtpe BNCT radiation treatment planning environment
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cB,blood 10B concentration in blood
Cross section Probability of a given type of interaction for the target nucleus concerned
CT Computed tomography
Dg Total absorbed gamma dose
Dn Total absorbed neutron dose
DN Absorbed dose from the nitrogen capture reaction
Dg,H Absorbed gamma dose from the hydrogen capture reaction
Dg,capture Absorbed gamma dose from the capture reactions
Dg,beam Absorbed gamma dose from photons in the beam
Dfast_n Absorbed fast neutron dose predominantly from recoil protons
DW Total weighted dose

calc
fDRe  Calculated dose rate at the reference monitor unit rate
DORT Two-dimensional discrete ordinates transport code
E Energy
ENDF/B Evaluated nuclear data file cross section library
fn(E) Neutron kerma factor or fluence-to-kerma factor
fB,ppm 10B kerma factor for 1 ppm 10B concentration
fN Nitrogen kerma factor
ffast_n Fast neutron kerma factor
(E) Neutron fluence rate
th Thermal neutron fluence
FiR 1 Finnish research reactor located in Otaniemi, Espoo
FiR(K63) Collimated epithermal neutron beam with 63-cm-long moderator at FiR 1
FiR(K75) Collimated epithermal neutron beam with 75-cm-long moderator at FiR 1
FiR(P75) Uncollimated epithermal neutron beam with 75-cm-long moderator at FiR 1
GBM Glioblastoma multiforme
HFR High Flux Reactor located in Petten, The Netherlands
IC Ionisation chamber
ICRU International Commission on Radiation Units and Measurements
INEEL Idaho National Engineering and Environmental Laboratory
IRDF-90 International reactor dosimetry file cross section library
Kerma Kinetic energy released per unit mass
Kn Neutron kerma
kB,tumour-to-blood 10B concentration ratio of tumour-to-blood
kB,brain-to-blood 10B concentration ratio of normal brain-to-blood
LET Linear energy transfer
6Liquid A Brain equivalent tissue substitute liquid without minor elements
Liquid B Brain equivalent tissue substitute liquid with minor elements
MC Monte Carlo
MCNP A general Monte Carlo n-particle transport code
MITR-II Massachusetts Institute of Technology Research Reactor located in Boston,
USA
MR Magnetic resonance
MU Monitor units
fMU Re

Reference monitor unit rate
NCT Neutron capture therapy
PET Positron emission tomography
PMMA Polymethylmethacrylate
PTV Planning target volume
rAu-197 197Au(n,) activation reaction rate
rMn-55 55Mn(n,) activation reaction rate
RBE Relative biological effectiveness
rtt_MC Radiation transport in tissue by Monte Carlo
SERA Simulation environment for radiotherapy applications
TLD Thermoluminescent detector
TORT Three-dimensional discrete ordinates neutron/photon transport code
TPS Treatment planning system
TS Tissue substitute
VTT Technical Research Centre of Finland
w-% Percentage by mass
wi Experimental weighting factor of the absorbed dose Di
1SD One standard deviation
2D Two-dimensional
3D Three-dimensional
7AIMS OF THE STUDY
The aim of this thesis was construction of the calculation model using the FiR 1 epithermal
neutron beam for treatment planning in neutron capture therapy (NCT).
Specific aims of the study were as follows:
1)  to create the FiR 1 epithermal neutron beam model and experimentally validate the free
beam neutron spectrum (Study I)
2)  to examine suitable brain tissue substitutes for NCT dosimetry (Study II)
3)  to verify absorbed doses of the complete beam model in a phantom (Study III)
4)  to transfer the beam model to a treatment planning system (TPS) and to validate and
normalise the computed doses in TPS to measurements (Study IV)
5)  to validate the dose planning chain of epithermal neutron irradiation without a boron
carrier and to estimate uncertainties of computed dose components in NCT (Study V and
Study VI)
6)  to apply the FiR 1 beam model to BNCT treatment planning (Study VII)
81 INTRODUCTION
In 1899, four years after the discovery of X-rays, the first patient was reported to be cured
using external radiation therapy [1]. Radiation therapy uses ionising radiation to treat patients
with malignant tumours and selected benign diseases. The aim of radiotherapy is to deliver a
accurate dose of irradiation in a defined tumour volume to destroy the tumour while causing
minimal damage to surrounding healthy tissues [1]. In addition to X-rays, particles, such as
electrons, neutrons, protons and light ions, have been used in external radiotherapy [2]. The
rationale for the use of neutrons in preference to conventional X-rays is that neutron
irradiation more effectively destroys radioresistant tumour cells [3]. The first clinical trials of
fast neutron therapy started in 1938, six years after the discovery of neutrons by James
Chadwick [4].
Like photons, neutrons have an influence indirectly through charged secondary particles. In
conventional radiation therapy, megavoltage X-rays interact in tissue with atomic electrons
mainly through the Compton effect and pair production [5]. Neutrons interact with atomic
nuclei and induce nuclear particles, such as protons, -particles and heavier nuclear recoils
[6]. Neutron interactions include 1) capture in which the neutron is captured by a nucleus with
emission of -radiation or with emission of proton irradiation (dominates at low energies), 2)
elastic scattering, in which a recoil proton is produced in a collision of a neutron primarily
with hydrogen nuclei and to a lesser degree with heavier atoms, 3) inelastic scattering, in
which some of the energy is converted into -radiation or the nucleus is left in an excited state
and 4) non-elastic interaction, in which nuclear reactions cause the emission of other particles
[6].
Neutrons can be classified according to their kinetic energy as thermal (E<0.5 eV), epithermal
(0.5 eV<E<10 keV) and fast (E>10 keV). The neutron dose Dn in tissue is equal to the neutron
kerma Kn under the charge particle equilibrium [5],
Dn = Kn = ,)()(
E
n dEEEf                                                           (1)
where fn(E) is the neutron kerma factor (also called the fluence-to-kerma factor) for the
interaction in matter, and (E) is the neutron fluence rate. The two most important interactions
of thermal neutrons in tissue are the neutron capture by nitrogen 14N(n,p)14C*, and the neutron
capture by hydrogen 1H(n,)2H. In neutron capture therapy (NCT), the dose in tissue induced
by the former reaction is called a nitrogen dose DN, and by the latter a hydrogen capture
gamma dose Dg,H. The kinetic energy of the proton from nitrogen capture is 0.58 MeV and
proton range is approximately 10 m in tissue. The kinetic energy of the hydrogen capture
gamma ray is 2.2 MeV [5]. In addition to Dg,H, the minor contribution of the gamma dose
from the other neutron capture reactions Dg,capture in tissue elements (e.g. chlorine) is induced
(Study II). From 40 eV to the higher neutron energies, the elastic scattering of neutrons with
hydrogen nuclei 1H(n,n’)1H begins to dominate the neutron kerma contribution in the brain
tissue (Figure 1). In NCT, the dose component in tissue from this reaction is called the fast
neutron dose Dfast_n. The contributions of oxygen-16 (16O) and carbon-12 (12C) are negligible
(<1%) to the absorbed dose in tissue in the epithermal neutron beam with a low fast neutron
dose contamination per epithermal neutron fluence rate epi (Dfast_n/epi = 2.1 x 10-13 Gycm2).
In addition to the neutron-induced doses in tissue, gamma rays in the incident neutron beam
cause the so-called beam gamma dose Dg,beam. The beam gamma rays originate from the
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materials in the reactor. Dg,beam can cause up to 50% of the total gamma dose Dg in tissue in an
epithermal neutron beam [7].
Figure 1. Relative kerma per unit neutron fluence of the adult brain tissue (solid line) and of
the five main atomic isotopes of the brain tissue [8, 9]: nitrogen-14 (open triangle),
hydrogen-1 (open square), carbon-12 (solid square), phosphorus-31 (open circle) and
oxygen-16 (solid triangle).
The concept of NCT was first published by Locher in 1936 [10], who proposed the use of
slow neutrons with strong neutron absorbers (e.g. boron, gadolinium) injected into tissue for
selective destruction of cancerous tissues. To date, only boron has been used in NCT clinical
trials of brain tumours, mostly glioblastoma multiforme (GBM), and melanoma [11-14].
Boron-10 (10B) has a high cross section for the boron neutron capture reaction, 10B(n,)7Li, at
thermal neutron energies. The ranges of the high-LET  and 7Li particles in tissue are
approximately 9 and 5 m, respectively, and the energies of the reaction are 2.3 MeV (94%)
and 2.8 MeV (6%) [15]. The 0.48 MeV gamma ray is emitted in 94% of boron capture
reactions, but the contribution to Dg is negligible. In boron NCT (BNCT), a boron delivery
agent is injected into a patient’s blood circulation, from where it accumulates in tumour cells,
which are then externally irradiated with low-energy neutrons. If boronphenylalanine-fructose
(BPA-F) is used as a delivery agent in BNCT of a GBM patient, the 10B concentration in a
viable tumour can be approximately four times more than in whole blood 0.5-1.5 hours after a
2-hour intravenous infusion, but it has considerable variation in the proportion of necrotic
tissue [11, 16]. The 10B concentration in a normal brain is slightly less than in blood [11].
When the dose from the boron neutron capture reaction (boron dose, DB) is calculated in a
tumour, the 10B concentration ratio of tumour-to-blood kB,tumour-to-blood is assumed to be 3.5 and
the ratio for the normal brain-to-blood kB,brain-to-blood 1.0 in order to calculate the dose in
normal brain vascular endothelium [11]. If the 10B concentration in blood cB,blood is assumed to
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be 12 ppm on average during irradiation, DB is approximately 75% of the total absorbed
tumour dose at the dose maximum (Study VII).
From the 1950 up to 1994, only thermal neutron beams were used in BNCT. However, the
dose distribution of the thermal neutrons was poor; the boron dose in tissue decreased to half
in 2 cm [2]. To minimise the poor penetration of neutrons, the irradiation was given at the
same time as craniotomy in Japan [2]. Epithermal neutrons were first utilised in USA in 1994
(MITR-II and BMRR) [15]. The epithermal neutrons thermalise in tissue and are captured by
10B, causing DB. The maximum DB of the epithermal neutrons is approximately at a 2-cm
depth in tissue and DB reduces to half at 5-7 cm [17, 18]. The neutrons utilised so far in BNCT
are produced by fission reactors in USA, Japan, the Netherlands, Finland, Sweden and the
Czech Republic, but accelerator-based epithermal neutrons sources have also been under
development [19-21].
In the recent decade, computational three-dimensional (3D) radiation treatment planning has
increased significantly. Patient tomographic data are required to make an anatomical model of
a target with planning target volume (PTV) [22] for the computation of 3D dose distribution.
Transversal images are usually used [23]. In photon and electron therapy, CT images are
utilised since they include information about the electron density of tissues. Thus, individual
information about tissue contents is available to compute the dose distribution. For BNCT,
several kinds of images are needed. With CT images, soft tissues, bones and air cavities, in
which neutron transport differs, can be distinguished. However, CT data are inadequate to
define the individual tissue compositions in BNCT since the images do not include atomic
nuclear information. With MR images, by contrast, soft tissues and macroscopic tumour areas
can be differentiated sufficiently well for the purposes of treatment planning. In the BNCT
treatment plan, the information about boron distributions has been described as homogeneous
inside the outlined tissues. The tissue-specific 10B concentrations are based on the tissue-to-
blood ratio of biological models [24]. However, the boron distribution in tissues is patient-
specific and the treatment plan would be enhanced by including this information. The current
BNCT treatment planning system (TPS) applies only one type of image at a time; however,
future plans will include adding boron localisation data derived from PET images [25]. In the
Finnish BNCT GBM research, MR images have been used in the TPS [26]. An anatomic few-
region computational model of the patient’s head with PTV and the tumour volume is
delineated, and the tissue composition is defined according to ICRU 46 [8].
To produce the dose distributions in a patient model, a beam description for TPS is required
[23]. The neutron capture therapy beams, generated at reactors, are individual beams with
beam-specific properties [27]. Therefore, the model of the beam construction is generated
using a neutron transport code. Specific methods have been utilised to solve the Boltzmann
transport equation in the geometrical model. Two of the most commonly used modelling
methods are the stochastic Monte Carlo method and the deterministic discrete ordinate
method [28]. A general Monte Carlo n-particle transport code (MCNP) [29] is a typical Monte
Carlo-based program for nuclear reactor simulations. The advantages of the MCNP are a
continuous cross section library at all energies and the capability to model complex
geometries. However, the statistical nature of the program requires extensive computer time to
achieve a low statistical uncertainty and the solution is achieved only in specific tallies
requested by the user [29]. The current TPSs used in BNCT are based on the Monte Carlo
method [14, 30]. The discrete ordinate method produces direction-, space- and energy-
dependent neutron and photon intensities at all points in the computational geometry [28]. The
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advantage of the discrete ordinate method is that in only a few hours computing time the
solution in the whole geometry is converged to a pre-set accuracy level. The discrete ordinate
programs ANISN, DORT and TORT have been used in the design studies of an epithermal
neutron beam [31-33]. The preliminary design of the Finnish epithermal neutron beam and the
optimisation of a neutron moderator material were done with ANISN and TORT [31].
The neutron-photon beam model was created based on the reactor model. The beam model
includes a description of the energy- and direction-dependent neutron and photon spectra. In
addition, the geometrical structures starting from the neutron-photon spectra source plane to
the beam entry are described in the beam model. The neutron spectrum of the beam can be
verified experimentally free in air [34]. Prior to use in patient treatment planning, the beam
model needs to be validated experimentally in a situation similar to the patient radiation
treatment. The validation is done in phantom measurements. International recommendations
for NCT dosimetry are still underway [35].
The computation of dose distributions for BNCT is a complex 3D problem since the dose
components have different spatial distributions and biological responses [28]. In treatment
planning, the distributions of dose components (Dg, DB, DN and Dfast_n) are computed in a
geometric model of a patient’s head (or body). Each dose component in tissue is weighted
using experimental factors to get an approximate photon-equivalent dose that can be summed
with the other dose components to get the total weighted dose DW. The weighting factors of
gamma (wg), nitrogen (wN) and fast neutron doses (wfast_n) are equal for all tissues, but DB has
a tissue- and compound-specific weighting factor (wB) [24]. DW is a sum of the
radiobiologically weighted dose components,
DW = wgDg + wBDB + wNDN + wfast_nDfast_n,                                        (2)
and the absorbed dose components are:
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where kB,tissue-to-blood is the 10B concentration ratio of tissue-to-blood, fB,ppm(E) is the 10B kerma
factor for 1 ppm 10B concentration,  fN(E) is the nitrogen kerma factor and ffast_n(E) is the fast
neutron kerma factor. Tables of kerma factors are published in literature, e.g. ICRU 46 [31].
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Figure 2. Scheme of the BNCT dose calculation.
The scheme of the dose calculation in the treatment planning system used in the Finnish
BNCT (Study VII) is described in Figure 2. The elements that the user can influence in the
dose calculation are neutron-gamma source, head model including tissue compositions, 10B
concentrations in tissues and weighting factors.
The BNCT doses are reported with isodoses and dose-volume histograms in normal brain
tissue, in PTV and in tumour volume (Study VII). The tumour isodose distribution in BNCT
with BPA-F is presented on a transaxial MR image of a GBM patient in Figure 3.
Figure 3. Relative isodoses of the weighted total dose DW for a tumour of a GBM patient,
transaxial plane. The weights of the two fields are 0.6 (1) and 0.4 (2). Collimator edges are
outlined.
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The horizontal cylindrical model of the FiR 1 epithermal neutron beam was created using
DORT code [36] for computational dosimetry and BNCT treatment planning of brain
tumours. The neutron collimator was designed using this DORT model. To experimentally
validate the beam model, suitable brain tissue substitute (TS) phantom materials were
simulated. The computed thermal neutron fluence and neutron dose and gamma dose
distributions were verified with measurements in homogeneous phantoms consisting of three
TS materials (PMMA, water and brain-equivalent liquid). The neutron-photon source from
the DORT model was transferred to the treatment planning system. The experimental
validation of the TPS with the FiR 1 beam model was done using the phantom measurements.
The normalisation of the beam model to the measurements in a phantom was examined. The
chain of the dose planning procedure was extensively studied in a healthy tissue tolerance
study of the dog brain without the boron carrier. Finally, the TPS with the FiR 1 beam model
was applied in the BNCT treatment planning of human glioma patients in the Finnish BNCT
project.
In a previously published Ph.D. thesis in the Finnish BNCT project, the FiR 1 beam model
was applied as part of the investigations of 1) the applicability of thermoluminescent
dosimeters for BNCT [37], 2) the dose determinations in a phantom with twin ionisation
chambers [38], 3) the relative biological effectiveness of the beam for the canine brain [39]
and 4) the experimental dosimetry system and patient positioning [40].
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2 MODELLING OF THE FIR 1 EPITHERMAL NEUTRON BEAM
The epithermal neutron beam is generated at the Finnish research reactor (FiR 1), which is a
250 kW TRIGA Mark-II type of open pool light water-cooled and graphite-reflected nuclear
reactor (General Atomics Company, USA). The fuel elements in the reactor core are
asymmetrically loaded so that the fresh fuel rods are in the direction of the epithermal beam to
maximise beam intensity. The final configuration of the epithermal neutron beam FiR(K63) is
moderated with a 63 cm FLUENTAL™ moderator [31] and collimated by a bismuth (Bi)
cone [27]. FLUENTAL™ (69 w-% AlF3, 30 w-% Al and 1 w-% LiF, density 3 g/cm3) is a
neutron moderator material that was developed at VTT [31]. Mainly because of the
FLUENTAL™ moderator, a high-intensity, collimated epithermal neutron beam with low fast
neutron and gamma ray contamination has been achieved at the low power research reactor.
The FiR(K63) beam, completed in November 1997, was the first epithermal neutron beam
with all these characteristics to be utilised in BNCT.
A two-dimensional (2D) horizontal cylindrical model of the FiR 1 epithermal beam was
constructed with a DORT code [36] with a BUGLE-80 [41] coupled (47 neutron and 20
photon groups) cross section library. A forward-biased quadrature set (D166) was selected for
the collimated beam model (Study I). Three geometries of the beam in its different stages
were modelled, i.e. FiR(P75), FiR(K75), FiR(K63), and validated experimentally [17, 34, 42-
44]. FiR(P75) had a 75-cm-thick FLUENTAL™ moderator and was uncollimated. FiR(K75)
also had a 75 cm moderator and was collimated. The DORT models have been used in the
optimisation of the final thickness of the moderator [31], in the design of the beam collimator
and in the shielding of the facility [45]. In addition to the design computations, the DORT
models of the beam have been used in computational dosimetry and BNCT treatment planning
(Studies I-VII). For the most part, the clinically used FiR(K63) beam model is discussed in
detail in this thesis. The FiR(K63) beam has a 63-cm-thick FLUENTAL™ moderator and is
collimated.
The DORT model of the beam consists of a description from the reactor core to the beam exit
with a surrounding geometry (Study I). The model was divided into two parts, core and
moderator-collimator. The core model was a fission neutron source that was tailored to a
collimated epithermal neutron beam with the beam moderators and the collimator in the
second part of the model. The principle of changing the real 3D geometry, where the reactor
core is vertical cylindrical, to the horizontal cylindrical model was that the distances of the
structures in the epithermal neutron beam central line were real. The central line of the
cylinder model was the middle line of the core, the FLUENTAL™ moderator and the
collimator. The rectangle structures of the real geometry were adjusted in the radial direction
of the cylindrical model so that the volumes of the structures remained of equal size. This
solution with DORT code and BUGLE-80 library has been used earlier in the design and
evaluation of other epithermal neutron beams facilities for BNCT [32, 33, 46]. The FiR 1
graphite reflector with an air-filled irradiation ring around the active core and a tangential air
tube between the active core and the moderators were modelled so that the graphite densities
were reduced to correspond the averaged densities of the modelled areas in the direction of the
beam. Initially, the FiR 1 core was modelled to be homogeneous and no air-filled structures
(tangential tube and irradiation ring) in the area of the graphite reflector were taken into
account. The first measurements showed a 50% underestimation in the beam intensity of the
initial model [42], therefore, a more detailed model of the core was constructed. The most
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essential details of the core model and the collimator design are explained in sections 2.1 and
2.2.
2.1 Core as neutron source
The core model includes the active reactor core, the graphite reflector with the irradiation ring
and the tangential tube, part of the moderating water and the initial part of the epithermal
column with aluminium frame, a boral plate (thermal neutron absorber) and part of the
neutron moderator. The atom densities of the fuel rods are based on the burn-up of the rods
(Study I).
The vertically cylindrical reactor core contains 79 three-types of fuel rods with
zirconiumhydrid, four B4C control rods, four graphite rods and four other rods surrounded by
light water. The fuel rods consist of twenty-three 12 w-% uranium (U) rods (steel shell), seven
8.5 w-% U rods (steel shell) and forty-nine 8 w-% U rods (Al shell). The uranium-235 (235U)
enrichment is 20 w-% [47]. The fuel rods in the reactor core are loaded asymmetrically so that
the freshest fuel rods are loaded in the direction of the beam (Figure 4). The initial MCNP
computation showed that the oblique fuel loading increases the neutron intensity in the beam
direction by 30% as compared with basic fuel loading, where the freshest fuel rods are in the
middle rings of the core [47].
Figure 4. Core loading of the FiR 1 reactor and active core zones (C1-C7) of the DORT core
model. The 79 fuel rods consist of 12% U (two dots), 8.5% U (one dot) and 8% U rods that
are asymmetrically loaded.
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The asymmetrical core rod loading was taken into account in the DORT model. The rods in
the core model were divided into the seven zones (Figure 4). The basic idea to divide the rods
into these zones C1-C7 was that the same types of rods be in the same zone and that distant
rods from the beam central line be put into separate zones (C1, C5). The water around the rods
was included in the core zones. The fuel rods with the highest 235U concentration were in zone
C7. The 235U contents of the individual fuel elements compared with fresh 12 w-% U fuel rods
were 52-57% (C1), 53-57% (C2), 52-94% (C3), 54-93% (C4), 54-57% (C5), and 56-100%
(C7). Zone C6 did not include fuel elements. The percentage sizes and 235U atom densities of
the core zones (C1-C7) in the heterogeneous core model compared with the initial
homogenised core zone are shown in Table 1.
Table 1. Percentage sizes and 235U atom densities of the core zones (C1-C7) in the
heterogeneous core model as compared with the average 235U atom densities in the
homogenised core model. Atom density of 235U in the homogenised core zone was 1.41 x 1020
atoms/cm3.
C1 C2 C3 C4 C5 C6 C7
Size, % 20 11 12 9 20 2 26
U235, % 81 79 97 91 83 0 150
Two control rods (B4C) were in zones C2 and C4. Two other control rods in zones C4 and C7
are up (not in use) when the reactor is running so they were included in the model as water.
Zone C6 consisted of only two graphite rods, and the two other graphite rods were in zones
C1 and C5. One (central rod) of the four other rods is filled with water and two with air, and
one (neutron source) is entirely water without a shell.
Around the reactor core is a graphite reflector ring which reflects escaping neutrons to the
core to take part in the fission reactions (Study I). The air-filled tangential tube, between the
core and the moderators, and the air-filled irradiation ring around the core were included in
the heterogeneous core model. The air volumes in the tube and the ring were included in the
core model by reducing the graphite densities. The graphite reflector in the beam direction
was divided into four graphite zones (Study I). A thin graphite layer (C) between the core and
the tangential tube was 100% graphite to achieve a full reflection of fission neutrons back to
the reactor core. The reduced densities of the three graphite reflector zones due to the
tangential tube and irradiation ring were calculated in the direction of the epithermal neutron
beam and used in the model. The graphite densities of the zones were 44.6%, 51.4% and
64.3% from the central axis to outwards in the radial direction. In Study I Figure 2a, the
graphite density of the middle zone was misprinted.
When converting the homogeneous core model to heterogeneous ones (C1-C7), the thermal
neutron fluence rate th increased in a phantom at the beam exit by a factor of 1.35. This result
was in agreement with the initial MCNP simulation [47]. The reduction of graphite densities
(use of real densities) between the core and the moderator increased beam intensity by 15%.
Thus, when the heterogeneous core model was used and the optic densities of graphite
reflector were taken into account, the beam intensity increased 50% and was in agreement
with initial measurements in the FiR(P75) beam geometry [42].
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2.2 Beam tailoring with moderator and collimator
In the second part of the DORT model, the fission neutrons were moderated to the collimated
epithermal neutrons (Study I). The purpose of these geometrical structures is to achieve a
high-intensity, well-collimated epithermal neutron beam that has a very low fast neutron and
photon contamination in the beam. In the first stage (1996) of the collimated beam, FiR(K75),
the moderator thickness was 75 cm. The dosimetric measurements revealed that the fast
neutron contamination in the beam was very low (Dfast_n/epi = 1.0  10-13 Gycm2s) but that the
beam intensity (epi = 0.5  109 n/cm2s) should be increased [42, 43]. The DORT
computations predicted that shortening the moderator from 75 cm to 63 cm would increase the
intensity of th in a phantom, to which DB is directly proportional, at the thermal neutron
maximum by a factor of 2.0 and at 50% of the thermal neutron maximum by 2.04. Dfast_n/th in
a phantom, which describes the quality of the epithermal neutron beam, increased at the
thermal neutron maximum by a factor of 2.2. The moderator was shortened to 63 cm and the
measurements confirmed that the free beam epithermal neutrons, which thermalise in a
phantom, doubled their intensity (Study I).
The conical Bi collimator with lithium-polyethylene shielding was designed with the
FiR(K75) model. A well-collimated epithermal neutron beam increases the desired thermal
neutron fluence (and the boron dose) at the depth in tissue per entrance neutron dose [32]. The
effects of collimator length on BNCT doses in a head-size PMMA phantom and on beam
forwardness (current-to-flux ratio) at the free beam exit were examined using a circular 14-
cm-diameter beam. The Bi collimator lengths were 25, 47 and 103 cm, with corresponding
cone angles of 96, 62 and 31. The Bi collimator thickness was fixed to 7 cm. In Table 2,
the effects of collimator length on BNCT doses relative to the doses of the 103-cm collimator
and the free beam current-to-flux ratios for each collimator length are presented. The planned
minimum current-to-flux ratio of 0.75 was achieved with the 47-cm-long collimator (Table 2).
Using the 25-cm-long collimator, DB was almost five times higher than using the 103-cm-long
collimator, the latter of which would provide a very good current-to-flux ratio (0.85). The
undesirable Dfast_n at the surface can be decreased with the more collimated beam, i.e. with a
higher current-to-flux ratio, as a previous study suggests [32].
Table 2. Effect of collimator length on BNCT doses in a phantom. DB, DN, Dg and Dfast_n are
presented relative to those of a 103-cm collimator. Current-to-flux ratios at the free beam exit
are for each collimator length.
Length,
cm
DB and DN
at 2.5-cm depth
Dg
at 2.5-cm depth
Dfast_n
at 0-cm depth
Current-to-flux
at free beam exit
25 4.69 4.74 5.84 0.67
47 3.16 3.20 3.47 0.75
103 1.00 1.00 1.00 0.85
The highly collimated beam reduced beam intensity significantly (Table 2). Intensity can be
improved with the thicker Bi collimator, which reflects neutrons back to the beam. In Table 3,
the effects of collimator thickness (0, 7 and 10 cm) on BNCT doses in the phantom with a 47-
cm-long Bi collimator are presented. The comparison revealed that the 7-cm- and 10-cm-thick
Bi collimators increased DB by 43% and 57%, respectively, compared with the bare conical
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lithiated polyethylene collimator with no Bi layer. The avoided Dfast_n at the surface of the
phantom increased more than the desired DB in the phantom with the Bi layer.
Table 3. Effect of collimator thickness on DB, DN, Dg and Dfast_n in a phantom. The dose
componets are presented relative to those of the collimator with no Bi layer.
Thickness,
cm
DB and DN
at 2.5-cm depth
Dg
at 2.5-cm depth
Dfast_n
at 0-cm depth
10 1.57 1.53 1.73
7 1.43 1.40 1.58
0 1.00 1.00 1.00
As a compromise between the intensity and collimation of the beam, the 46.6-cm-long
collimator with a 60 angle was constructed [27]. A 7-cm-thick Bi collimator (approximately
500 kg) was chosen. The 10-cm-thick Bi collimator layer would increase beam intensity by
10% compared with the 7-cm Bi collimator, but the weight of the Bi collimator would rise to
750 kg. The final current-to-flux ratio was calculated to be 0.77 at the exit plane of the 14-cm
aperture.
2.3 Experimental validation of free beam spectrum
The FiR(K63) free beam neutron spectrum at the beam entry was measured as described in
Study I. Comparisons of the calculated and the experimental thermal (E<0.5 eV), epithermal
(0.5 eV<E<10 keV) and fast (E>10 keV) neutron fluence rates are presented in Table 4. The
experimental values are the most recent and have changed slightly from the values in Study I
because of small modifications to the adjustment data (e.g. tungsten decay data).
Table 4. Calculated (C) and experimental (E) ( 1SD) neutron fluence rates  at the beam exit
plane of the 14-cm aperture.
, n/cm2s Ratio
C E C/E
Fast Neutrons 3.20  107 3.45  107 (31%) 0.93
Epithermal Neutrons 1.03  109  1.07  109 (5%) 0.96
Thermal Neutrons 6.65  107 7.19  107 (21%) 0.92
Previous DORT computations with BUGLE-80 cross sections of the epithermal neutron beam
with an aluminium-oxygen neutron moderator underestimated the fast neutron component by
30-50% [32, 33, 46]. As suggested by Nigg et al. [46], the problem is not as severe with an
aluminium-fluorine moderator. Experimental validation of the free beam spectrum showed
that the calculations and the measurements of energy groups were in good agreement (Table
4). Comparative measurements of the INEEL dosimetric group (Idaho Falls, USA) confirmed
the good agreement of experimental and computational fluence rates [48].
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3 VERIFICATION OF BEAM MODEL IN PHANTOMS
The FiR(K63) epithermal neutron beam has five fixed sizes of circular fields for irradiation.
The available diameters of the beam are 8, 11, 14, 17 and 20 cm. The 11-cm and 14-cm-
diameter beams were selected for use in the BNCT of brain tumour patients. It was decided
that in BNCT a patient‘s head should be next to the beam aperture since the beam is
somewhat diverging, and if a patient is moved further away, treatment times become longer
and the dose to healthy tissues increases with aperture size. Therefore, a phantom that is used
for dosimetric validation of the beam model is also placed next to the beam exit plane.
Generally, a beam in BNCT has been characterised in a TS phantom by measuring the thermal
neutron fluence th, gamma dose Dg and fast neutron dose Dfast_n in the central axis of a
phantom under reference conditions [18, 49]. With the exception of Dfast_n and the beam
gamma dose Dg,beam, all significant dose components in BNCT are induced from th generated
in the irradiation volume [32]. Because the fast neutron and gamma ray contaminations in the
FiR(K63) beam are very low (Dfast_n/epi = 2.1 x 10-13 Gycm2s, Dg/epi = 0.5 x 10-13 Gycm2s)
[27, 50], characterisation of th in a phantom is especially important. However, experimental
validation of the computed gamma and neutron doses in phantoms assures that the fast
neutrons and gamma rays in the beam are correctly modelled. In addition, validating that the
thermal neutron-induced doses in a phantom and in tissue are correctly computed in a TPS is
important.
3.1 Tissue substitute phantom materials
Prior to the dose planning in tissue, the computations were validated with dosimetric
measurements in TS phantoms. In photon and fast neutron therapy, water is used as a
reference phantom material [51]. The TS phantoms are used for experimental validation of a
beam model, dose calibration and quality control. TS phantoms are also used in dosimetric
intercomparison of epithermal neutron beams, which is underway in the European Code of
Practice project [35]. In NCT dosimetry, no commonly accepted recommendations for TS
phantoms exist, therefore, a suitable TS material was studied (Study II). In previous
experimental NCT dosimetric studies [49, 52, 53], both water and PMMA
(polymethylmethacrylate) were used as phantom material. Both materials have shortcomings
compared with adult brain tissue content as defined by ICRU 46 [8] in their elemental
compositions. For example, nitrogen and minor elements (P, Na, Cl, K, S) are absent in water
and in PMMA. In addition, the hydrogen atomic density is 15% lower in PMMA and 1.5%
higher in water than in brain tissue [8]. As a consequence of these shortcomings, two new
brain TS liquids were designed from chemical compounds (Study II). Both brain TS liquids
(Liquids A and B) contained equal atomic densities to adult brain tissue of the main elements
(H, O, C, N) [8]. Moreover, Liquid B included an equal amount of minor elements as in brain
tissue [8]. The dose components in Liquid B were more similar than those in Liquid A to the
ones in brain tissue, therefore Liquid A was excluded from future studies.
The computational comparison of neutron and photon transport calculations in these four
brain TS candidates and in brain tissue predicted that Dg was 24-28% lower in PMMA than in
brain tissue at the thermal neutron maximum (Study II). This variation is explained by
differences in the neutron beam spectrum and gamma ray contamination in the beam. Both
beams were uncollimated and one was the FiR(P75) beam with a simple delimiter (Beam 1 in
Study II). The thermal neutron maximum was at 1.5-cm depth in the uncollimated beams. The
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Dg was 10-12% lower in water than in brain tissue [8] at a depth of 1.5 cm. Water simulated
th in the brain tissue 2 percentage units closer than PMMA at the thermal neutron maximum.
In all tissues, fluence-to-kerma conversions to brain tissue were computed only to study the
effect of neutron and photon transport calculations.
The TS phantom study (Study II) was repeated using the SERA treatment planning system
(INEEL/MSU, USA) [25] with the collimated FiR(K63) epithermal neutron beam in the
cylindrical phantoms (diameter 20 cm, length 24 cm) (Figure 5). The liquids were covered
with a 0.5 cm PMMA frame. The thermal neutron maximum in the phantoms shifted to a
depth of 2.0 cm in the collimated beam. In this set-up, the computed Dg was 21% lower in
PMMA, 9% lower in water and 2% lower in Liquid B than in brain tissue at a depth of 2.0
cm. The computed th was 3% higher in PMMA, 6% higher in water and 0.2% lower in
Liquid B than in the brain tissue (Figure 5). In the collimated beam, PMMA simulated th in
the brain tissue at the thermal neutron maximum 3 percentage units closer than water. This is
contrary to the observation in the uncollimated beam (Study II). The brain tissue-equivalent
liquid (Liquid B) simulated excellently th and Dg in the brain tissue both in the collimated
and the uncollimated beams.
Figure 5. Percentage difference of the thermal neutron fluence th (left) and the gamma dose
Dg (right) in PMMA (diamond), water (square) and Liquid B (triangle) phantoms compared
with the corresponding values in adult brain tissue [8] in the central axis of the cylindrical
phantom in the collimated 14-cm-diameter FiR(K63) beam.
Raaijmarkes et al. [54] studied the influence of composition of the phantom material in the
high flux reactor (HFR) well-collimated epithermal neutron beam. In their beam, the thermal
neutron maximum was at a depth of 2.0 cm in a tissue-equivalent (TE) phantom. th in a
PMMA phantom was 1% lower, Dg 12% lower and Dfast_n 3% lower than in the water
phantom. This is consistent with the phantom computations in the FiR(K63) beam. Small
differences are explained with differences in neutron spectra and uncertainties in
fluences/doses.
The PMMA, water and Liquid B phantoms were manufactured for the dosimetric
measurements at the FiR 1 facility. Kortesniemi et al. [44] measured the gamma depth doses
in the 14-cm FiR(K63) beam. The measurements showed that Dg was 10% lower in water and
20% lower in PMMA than in Liquid B at a depth of 2.0 cm of the cylindrical phantoms. These
Dg differences agreed well with the SERA computations explained above. The activation foil
measurements showed that th was 10% higher in water and 6% higher in PMMA than in
Liquid B at a depth of 2.0 cm (Study IV). Uncertainty of the measured th was estimated to be
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4% (1SD) [44]. Measurement showed differences a few percentages higher in th of
phantoms than the computations had predicted, but these were still within the measurement
uncertainties. According to both computations and measurements, th was 3-4% higher in
water than in PMMA.
In conclusion, at the thermal neutron maximum, PMMA simulates th in brain tissue slightly
better (3 percentage units closer) than water, but water simulates Dg in brain tissue better (12
percentage units closer) than PMMA in the collimated FiR(K63) beam. From the perspective
of measurements, the PMMA phantom was more practical to use than the water phantom. The
spatial accuracy of the detectors in solid material is superior to that in liquid. In addition, in
liquids the detectors needed to be fixed to a measurement position with solid support
materials, which might disturb the fluence/dose distributions of a homogeneous phantom
material. Even though the brain-equivalent liquid (Liquid B) simulates the fluence/dose
distributions in brain tissue well, the uncertainty of its composition was greater than that of
water. Following advances in water, PMMA and Liquid B, all of these materials have been
used in the experimental validation of the FiR 1 beam model and the computations in a
phantom. Of these materials, PMMA was chosen for the normalisation of the beam model to
activation measurements. The normalisation beam model is discussed in more detail in section
4.3.
3.2 Experimental verification
At least four activation foil/wire measurement techniques in a phantom have been used in
epithermal neutron dosimetry at the clinical BNCT facilities. Liu et al. [52] at BMRR and
Rogus et al. [49] at MITR-II have applied gold foils using the cadmium difference technique
[5]. Raaijmarkers et al. [53] have also studied the two-foil method at HFR and have chosen
this method in clinical NCT dosimetry with gold-aluminium (Au-Al) (5 w-% Au) and
manganese-nickel (Mn-Ni) (88 w-% Mn) foils [18]. In intercomparative phantom
measurements at FiR 1, Nigg et al. [17] used copper-gold wires with computed effective cross
sections for flux wire materials.
In Finnish dosimetric measurements, diluted Au-Al (1 w-% Au) foils have been applied to
determine th in a phantom. Neutron spectra were computed in 47 BUGLE-80 energy groups
using the DORT model at the measurement locations of a phantom. The 197Au(n,) activation
reaction rates rAu-197 were calculated by multiplying the computed neutron fluence rates and
the corresponding spectrum-weighted activation cross sections in energy groups. The
weighting spectrum at a depth of 2.5 cm in a phantom was used to condense the 640-group
activation cross section data from the IRDF-90 library [55] to the 47 BUGLE-80 neutron
groups. The method is described in Study III more precisely. The measured th was
determined by scaling the computed th by the ratio of the measured and the calculated
197Au(n,) activation reaction rates at the measurement location. The uncertainty of the
measured th in a phantom was estimated to be 4% (1SD) [44]. All the measured values used
for the validation of computed values are reported at the reference monitor unit rate (reactor
power approximately 250 kW). The calculated neutron fluence rate  was normalised to the
reference monitor unit rate fMU Re

 [56] by the ratio of the measured and the calculated
197Au(n,) activation reaction rates at the thermal neutron maximum of the PMMA phantom
(diameter 20 cm, depth 24 cm) (Study IV). A value of 0.95 for the ratio was determined for
the circular 11-cm- and 14-cm-diameter beam models of the FiR(K63) DORT model.
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The analysing method described above of the measured th at the FiR 1 is dependent on the
calculated DORT spectrum. It is practical method since only one measurement and one foil
type are needed. However, the method is dependent on the computations and it assumes that
the shape of the calculated neutron spectrum is correct. The validation of the neutron fluence
can be done independently when the activation reaction rates are compared. The method
becomes more reliable when two different energy-dependent foils are used; thus, diluted Mn-
Al (1 w-% Mn) foils were also applied. In Figure 6, the computed proportional responses of
the epithermal (0.414 eV<E<10 keV) and the thermal (E<0.414 eV) neutrons for the
197Au(n,) and 55Mn(n,) activation reaction rates rAu-197 and rMn-55 at depths in the PMMA
phantom of the 14-cm FiR(K63) beam are shown. At a depth of 2.0 cm, 58% of rAu-197 and
97% of rMn-55 originate from the thermal neutrons, and the remainder is induced from the
epithermal neutrons. The fast neutron’s response (E>10 keV) for both activation reactions was
negligible (<0.01%).
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Figure 6. Proportional responses of the epithermal (0.414 eV<E<10 keV) and thermal
(E<0.414 eV) neutrons for the 197Au(n,) and 55Mn(n,) activation reaction rates r in the
central axis of the cylindrical PMMA phantom in the 14-cm FiR(K63) beam.
The DORT model of the FiR(K63) beam was verified with the Au and Mn activation reaction
rate measurements in the cylindrical (diameter 20 cm, length 24 cm) PMMA, water and brain-
equivalent liquid (Liquid B) phantoms (liquid phantoms were attached to the pool [44]). The
Mn foils were only used in the PMMA phantom that best simulates th in the brain tissue and
has the lowest uncertainty of the detector position. The uncertainty of the measured activation
reaction rate is estimated to be 3% (1SD). The verification of the model with a circular 14-cm-
diameter beam is presented in the central axis and in the selected off-axis points (depths of 2.5
cm and 6.0 cm) of the phantoms (Figure 7). The results of the comparison were similar to the
11-cm-diameter beam.
r, 
%
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Figure 7. Ratio of calculated (DORT) and experimental (C/E) 197Au(n,) and 55Mn(n,)
activation reaction rates r in three cylindrical phantoms in the 14-cm beam. The dotted lines
describe the measurement uncertainty of 3% (1SD).
The comparison showed (Figure 7) that near the thermal neutron maximum at a depth of 2.0
cm most of the C/E ratios were within the measurement uncertainty of 3% (1SD). At the beam
entry, the calculated reaction rates were systemically underestimated by about 5%. At deeper
depths in the phantom, the calculated reaction rates were overestimated by up to 16%. An
explanation for the ascending C/E ratios as a function of depth in Figure 7 is that only a single
weighting spectrum (at 2.5-cm depth) was used for the regrouping of the activation cross
sections for all depths and the BUGLE-80 library consists of only two thermal neutron energy
groups. The similar C/E ratios of rAu-197 and rMn-55 in the PMMA phantom predict that the
computed neutron spectra at the epithermal and thermal neutron energy areas were
approximately correct.
Water was observed to simulate the gamma dose Dg in the brain tissue considerably closer
(more than 10%) than PMMA in three different epithermal neutron beams (Figure 5 and Study
II). Thus, water was primarily used in the experimental validation of the absorbed gamma
dose. According to the computations in the 14-cm FiR(K63) beam, approximately 95% of the
gamma dose at the thermal neutron maximum in the water phantom originated from the
hydrogen capture reaction, 1H(n,)2H, and only 5% of the beam gamma rays. Therefore, the
uncertainty of the computed hydrogen capture gamma dose Dg,H is highly dependent on the
uncertainty of the computed th. The calculated and the measured th in the neighbourhood of
its maximum in the 14-cm beam were within 2.5%, the uncertainty of the measured th is 4%
(1SD) and the uncertainty of the used mass energy absorption coefficient is 1% for hydrogen
[8]. When considering these uncertainties, the combined quadratic uncertainty of the
calculated Dg,H around the thermal neutron maximum was estimated to be 5% in the water
phantom.
The calculated total neutron and gamma doses Dn and Dg to the brain tissue defined by ICRU
46 [8] were validated using twin ionisation chamber measurements in the phantoms (Study
III). The computed neutron spectra of the DORT model at the measurement locations in the
water phantom were used to determine the experimental neutron doses Dn. According to this
study, the uncertainties (1SD) of the measured Dn and Dg were estimated to be 6.3% and
21.5%, respectively. The comparison of the calculated (DORT) and the measured (ionisation
chambers, Exradin) gamma doses at the thermal neutron maximum showed that the calculated
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gamma dose was 5% higher than the measured gamma dose. In these computations, the beam
intensity adjustment was -3.6% based on the Au-Al activation foil normalisation (Study III).
However, additional Au-Al activation measurements (n=6) in the PMMA phantom increased
the beam intensity adjustment of the DORT model from -3.6% to -5.0%. After this new
intensity adjustment, the renormalised calculated gamma dose was only 3.5% higher than the
measured gamma dose at the thermal neutron maximum. To make the comparison more
reliable, the measurements should be extended to the surface direction in a phantom. In the
horizontal beam, this would be technically cumbersome because of the solid frame around the
water phantom and the large size of the IC detector. However, the comparison of the
measurements and calculation of absorbed gamma dose in the water phantom suggest that the
photons in the beam were modelled correctly within the IC measurement uncertainty of 6.3%.
In NCT, the total neutron dose Dn in tissue consists mainly of the nitrogen dose and the fast
neutron dose. The main part of Dn in the FiR(K63) beam is from the nitrogen capture since the
fast neutron contamination is very low [50]. The measured (pair ionisation chamber, Exradin)
and the calculated total neutron doses agreed well in the water phantom within the
measurement uncertainty of 21.5% (Study III). At the first measurement depth (2.0 cm), the
calculated Dfast_n dose was about 20% of the total neutron dose Dn. Since the amount of the
fast neutron dose of the total neutron dose and the measurement uncertainty are approximately
equal (~20%), the uncertainty of the calculated fast neutron dose Dfast_n remains large. At the
surface of the phantom, the calculated Dfast_n was 73% of the total neutron dose Dn; however,
comparison to the experimental IC data could not be made because of difficulties due to the
horizontal beam explained above. The experimental fast neutron fluence rate free in air agreed
well within the measurement uncertainty of 31% (Table 4). The uncertainty of the kerma
factors for hydrogen is 1% [8]. Therefore, the uncertainty of the calculated Dfast_n in a
phantom was estimated to be 31%.
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4 TRANSFERRING BEAM MODEL FOR TREATMENT PLANNING SYSTEM
The BNCT treatment planning has been performed with the Monte Carlo based 3D
computational treatment planning systems (TPSs) [14, 30]. In the Finnish BNCT project, the
BNCT_Rtpe software (INEEL/MSU, USA) was initially used in NCT and BNCT dose
planning. Its successor SERA (INEEL/MSU, USA) was later taken into use at FiR 1. The
main difference between the programs is that SERA uses approximately ten times less
computer time than BNCT_Rtpe. One field dose computation in SERA takes less than half an
hour depending on the required statistics [25]. The absorbed doses are calculated from the
energy-dependent fluence rate data and kerma factor data for each radiation dose component
[30]. The same beam model can be used in both TPSs. BNCT_Rtpe and SERA use neutron
and photon cross section data from the ENDF-IV/V/IV libraries that was pre-processed into
94 neutron energy groups: 22 thermal neutron groups (E<0.414 eV), 40 epithermal neutron
groups (0.414 eV <E< 9.12 keV) and 32 fast neutron groups (9.12 keV <E< 16.9 MeV) [57].
The spatial doses, fluences and activation reaction rates are tallied into the 3D virtual
subelement mesh that is composed of 30*30*30 cubic voxels (cube side 10 mm). In SERA,
both the subelement number and the voxel size can be changed [57]. However, the use of
smaller voxel sizes increases the computation time if the statistical uncertainty of the results is
kept constant.
4.1 Beam model geometry
The neutron-photon beam model of the FiR(K63) beam for the BNCT_Rtpe/SERA was
determined from the DORT beam model with the water phantom. The beam model of the 11-
cm and the 14-cm beams were defined in a similar manner for the TPS. The beam model of
the TPS is an averaged source plane over the airspace and was defined 5.0 cm inwards from
the beam exit plane (Study IV). The beam description includes the neutron and photon spectra
of the 47-neutron and 20-photon BUGLE-80 energy groups [41] and angular distributions of
all 67 energy groups in 10 cosines of equal probability direction from 1 to 0 [30] (Figure 8). In
addition to the spectral description, the TPS beam model includes a geometric description i.e.
the disk-shape beam plane and the 5-cm-thick conical Li-polythene collimator. The collimator
and the phantom were defined in the TPS with logical combinations of geometric primitives
(cylinder, cone…) [30].

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3...9
FOR 47 NEUTRON GROUPS
AND 20 PHOTON GROUPS
BEAM CENTRAL LINE
Figure 8. Neutron-photon beam description in TPS. Ten angular directions of the equal
probability current (I) are described at cosine cut-points (cos) for 47 neutron and 20 photon
energy groups.
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4.2 Verification in phantoms
The thermal neutron fluence has usually been determined with activation measurements, and
gamma Dg and the fast neutron doses Dfast_n with pair ionisation chambers [18, 49, 52].
Kosunen et al. (Study III) ended up determining total neutron dose Dn instead of the fast
neutron dose Dfast_n in a phantom. In BNCT treatment planning, the same weighting factor
(also called RBE in literature) has been used world wide for nitrogen and fast neutron dose
components DN and Dfast_n [11, 24]. Therefore, these dose components have not required
separate verification with measurements.
In BNCT_Rtpe and SERA, DN and Dfast_n are printed out separately [57]. In addition, the
neutron dose component known as the “other dose” can be printed in SERA. The “other dose”
includes absorbed neutron doses from carbon and oxygen in tissue at the fast neutron energies
[57]. The neutron dose from other minor isotopes (Na, P, S, Cl, K) in brain tissue [8] is
negligible [58]; therefore, the total neutron dose in SERA is a sum of DN, Dfast_n and the
“other dose”. The total gamma dose Dg in the BNCT_Rtpe and SERA programs consists of
the hydrogen capture gamma dose Dg,H and the beam gamma dose Dg,beam. In BNCT, the other
(n,) reactions in tissue occur at such a low probability that they make no significant
contribution to the gamma dose in tissue, and thus, are not included in Dg in the BNCT_Rtpe
and SERA programs [59]. Difference of the cross sections used in these TPSs is that the
photon cross section data has been switched from ENDF/B-IV (BNCT_Rtpe) to ENDF/B-VI
(SERA). This change brought about 3-5% reduction in Dg in SERA as compared with in
BNCT_Rtpe [60].
The initial SERA computations of the absorbed dose components in the water phantom
showed that the amount of the thermal neutron-induced dose DN + Dg,H varied between 90%
and 95% at depths of 0.5-10 cm of the water phantom in the 14-cm FiR(K63) beam. The rest
of the absorbed total dose in the water phantom consists of Dg,beam., Dfast_n and “other dose”,
and their respective portions are 2-5%, 2-7% and <1% at depths of 0.5-10 cm. The doses
reported here were computed for adult brain tissue as defined by ICRU 46 [8]. Since the
thermal neutron-induced doses in the brain tissue substitute (TS) phantom predominate, it is
important to validate the thermal neutron fluence distribution in a TS phantom. However, the
total gamma and neutron doses Dn and Dg in a phantom also need to be validated to assure the
non-thermal neutron fluence-induced dose distributions as well as the correctness of the dose
computations in the TPS.
The FiR(K63) beam models and the computations of the BNCT_Rtpe were experimentally
validated in the three homogeneous phantoms (Study IV). The diluted Au-Al activation foil
measurements were completed with the diluted Mn-Al foils as described earlier (section 3.2).
When either the diluted Au-Al or Mn-Al foil was excluded from the phantom model, the
disruption to the activation reaction rate rAu-197 or rMn-55 was computed in the DORT model to
be negligible (0.2%). Thus, the modelling of the foils in a phantom geometry was
demonstrated to be unnecessary. This was convenient because the foil size was very small
(0.023 cm3), and to get a good statistical result in a small volume would require a remarkably
long computing time. In addition, only the fixed subelement mesh (1-cm3 voxel) was available
in the BNCT_Rtpe software, therefore, the result inside the small size foil would vanish in the
averaged result of the relatively large unit voxel. The default 1-cm3 voxel was used in both
programs.
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The Monte Carlo based treatment planning program SERA has an option to compute rAu-197
and rMn-55. Therefore, the same beam normalisation method can be used as for the DORT
computation. In BNCT_Rtpe, this option was specially tailored to our group (Study IV). The
statistical analysis at the normalisation point at a depth of 2.0 cm in the PMMA phantom was
computed in SERA for the activation reaction rates and the doses to estimate the need of
histories to follow, since the program do not print the point statistical errors. This analysis was
possible since the computation times with SERA were reasonable. The analysis showed
(Figure 9) that at least 25 million histories were needed in a calculation to achieve a better
than 0.5% statistical uncertainty for rAu-197  and 5 million histories for rMn-55 at the thermal
neutron maximum. However, 50 million histories were needed to have the same normalisation
factor of 0.94 from both activation reactions. Lower number of histories, at least 5 million,
were needed to obtain a 0.5% statistical uncertainty of the dose components, except for the
fast neutron dose Dfast_n, which required four times as many histories to follow. This was due
to Dfast_n being very low (3% of the total dose at a 2.0-cm depth). In SERA, 50 million
histories were chosen to be followed in a simulation to compute the activation reaction rates
and 20 million to compute the absorbed doses in a phantom. Since both results are computed
in one computer run, 50 million histories were used for the phantom computations of the
beam validation and normalisation, which takes 17 hours by the SUN Ultra 60 computer.
However, for the optimisation of the field arrangement in the BNCT treatment planning, 0.5
million histories for a field have been found satisfactory, and the computation takes only 10
minutes of computer time. The final doses for the BNCT treatment plan are computed using 5
million histories per field in SERA.
Figure 9. Statistical analysis in SERA for the activation reaction rates r and the absorbed
doses D at the thermal neutron maximum (depth 2.0 cm) in the PMMA phantom of the FiR 1
14-cm beam.
The comparison of the calculated and the measured rAu-197 and rMn-55 showed a good
agreement in three cylindrical phantoms (Figure 10). Only at the beam entry point were the
calculated rAu-197 or rMn-55 6-19% higher than the measured. This is due to 1-cm3 (default
value) subelement voxels being used and the interpolation in the air-phantom material
interface being inaccurate (Study IV). The results of the comparison were similar for the 11-
cm-diameter beam and for the BNCT_Rtpe computations. In the DORT calculation (Figure 7)
where the foil-size tally voxel was modelled on the surface of the phantom, the calculated rAu-
197 or rMn-55 were 5% lower than the measured ones. The ascending C/E ratios as a function of
depth observed in connection to the DORT calculations were not observed here. This can be
explained by the thermal neutron cross sections being presented in 22 energy groups in SERA
and BNCT_Rtpe compared with the two groups in DORT computations.
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Figure 10. Ratio of calculated (SERA) and experimental (C/E) 197Au(n,) and 55Mn(n,)
activation reaction rates r in three cylindrical phantoms in the 14-cm beam. The dotted lines
describe the measurement uncertainty 3% (1SD).
The comparison of the calculated rAu-197 and rMn-55 with the measured ones describes the
quality of neutron spectra at the measurement location. When ratios of the calculated and the
measured rAu-197 and rMn-55 are the same for these two reactions, the neutron spectrum in the
thermal neutron energy area can be assumed to be correct. Since the calculation and the
measurement of rAu-197 and rMn-55 are independent of each other, the comparison is reliable.
Therefore, the first priority is to validate the thermal neutron spectrum with the 197Au(n,) and
the 55Mn(n,) activation reaction rates. Moreover, it is convenient to print out the calculated
and measured thermal neutron fluences and compare them, but one should note that a spatially
calculated neutron spectrum in 47 energy groups was assumed to determine the measured
thermal neutron fluence rate th. The measured th was determined by using rAu-197 as
described in section 3.2. Figure 11 compares the measured th to the computed ones in the
water phantom using the DORT model and the BNCT_Rtpe (rttMC) and SERA treatment
planning programs. The calculated values were normalised to the Au-Al activation foil
measurements at the reference monitor unit rate fMU Re

 in the PMMA phantom, at a depth of
2.0 cm, in each program separately. The calculations and the measurements were in a good
agreement, except at the surface of the phantom using BNCT_Rtpe and SERA, where the
computed fluence was overestimated by 39% and 36%, respectively.
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Figure 11. Thermal neutron fluence rates (E<0.414 eV) th in the central axis of the
cylindrical water phantom in the 14-cm FiR(K63) beam. Error bars represent 4.0%
uncertainty of measured values.
The method to measure the total neutron dose Dn and the total gamma dose Dg in NCT was
established in Study III. The calculated spatial neutron energy spectra in the phantoms were
required to determine the measured Dn. The spatial neutron spectra were computed in the
DORT model in BUGLE-80 energy groups. The IC measurements [44] were used to verify the
computed Dn and Dg in the three homogeneous phantoms. Figure 12 compares the measured
total neutron and total gamma dose rates with the computed ones using the DORT model and
the BNCT_Rtpe (rttMC) and SERA. The calculated values were normalised to the activation
measurements in each program separately as neutron fluences. The small difference in Dg in
the TPSs was explained with the different version of the ENDF cross section library [60]. In
addition to our group measurements, an excellent agreement of the computed (BNCT_Rtpe)
and the measured boron dose DB in the 11-cm FiR(K63) beam was demonstrated by the
INEEL dosimetry group in their comparable measurements [17].
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Figure 12. Total gamma (above) and neutron (below) dose rates at the central axis in the
cylindrical water phantom in the 14-cm FiR(K63) beam. Error bars represent 6.3% (gamma)
and 21.5% (neutron) uncertainties of measured doses (Study III).
4.3 Normalisation of beam model
Previously, at MITR-II [14] and at HFR [58], the TPS calculations in BNCT were normalised
in approximately human head sized phantoms. The calibration phantom was a PMMA cube
(size 15 cm) [58] or a water-filled, thin acrylic ellipsoid [14]. At HFR, the BNCT_Rtpe
calculations were normalised to a 2-cm depth in the calibration phantom with a 2200 m/s
(0.0253 eV) fluence rate [58] determined using the two-foil method (Au-Al (5 w-% Au) and
Mn-Ni (88 w-% Mn)) [53, 58]. At MITR-II, where the NCTPLAN [14] was used as a TPS, all
the dose components were calibrated separately based on the paired ionisation chamber
measurements in the calibration phantom [14, 49]. Both facilities used a beam monitor
system.
The beam models of the FiR 1 were normalised to a 2-cm depth, i.e. at the thermal neutron
maximum in the PMMA phantom (diameter 20 cm, length 24 cm), by the ratio of the
measured and the computed 197Au(n,) activation reaction rates at the reference monitor unit
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rate (Study IV). The PMMA phantom was chosen as a calibration tool as described in section
3.1.
The use of 197Au(n,) activation reaction rate rAu-197 for the normalisation of an epithermal
neutron beam in a phantom were justified because the uncertainty of rAu-197 is small (3% 1SD),
and the computed and the measured activation reaction rates are independent of each other.
The small size of foils (diameter 12 mm, thickness 0.2 mm) could be modelled as a phantom
material because their effect on reaction rates were negligible (0.2%). This was very important
for the Monte Carlo based treatment planning computations described in section 4.2.
The 55Mn(n,) activation reaction rate rMn-55 would be the first choice to normalise the
calculations since the energy response is mainly in the area of thermal neutrons (Figure 6),
which induce most of the absorbed doses. However, the activation cross section data of the
197Au(n,) from IRDF-90 [55] are better known with <1% uncertainty, whereas the uncertainty
of the 55Mn(n,) cross sections is < 4.5% at the energy area of interest.
The 197Au(n,) and 55Mn(n,) activation reaction rates rAu-197 and rMn-55 were examined using
different simulation programs and two cross section data of SERA. The two cross section data
used in SERA were from the 640-group IRDF-90 library [55]. The only difference in these
condensed 94-group cross sections for SERA was that a different weighting spectrum was
used. The original data of SERA is called “SERA orig. c.s.” and another cross section data is
named “SERA VTT c.s.”. The weighting spectrum for “SERA VTT c.s.”, described in Study
IV, is used in the computations in SERA and in BNCT_Rtpe at FiR 1. The calculated values
were compared with the experimental ones in the central axis of the PMMA phantom (Figures
13 and 14). In addition to the previously presented computations, the reaction rates were
computed using the MCNP program [29], which uses the continuous ENDF-VI cross section
library. The SERA/BNCT_Rtpe neutron beam model was also used in MCNP. The calculated
values were not normalised to compare only the computational effects between the programs.
Figure 13. Calculated and measured 55Mn(n,) activation reaction rates rMn-55 in the
cylindrical PMMA phantom in the 14-cm beam (left). Ratios of the calculated rMn-55 using
different programs are compared with experimental values (C/E) (right).
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Figure 14. Calculated and measured 197Au(n,) activation reaction rates rAu-197 in the
cylindrical PMMA phantom in the 14-cm beam (left). Ratios of the calculated rAu-197 using
different programs are compared with experimental values (C/E) (right).
rMn-55 was more program- and cross section-dependent than rAu-197. rAu-197 computed in SERA
with the original cross sections was 13% higher than in MCNP and 7% higher than in another
set of cross sections (SERA VTT c.s.) in SERA at a depth of 2.0 cm. The corresponding rAu-197
in SERA was 3% higher compared with MCNP, and the effect of the two cross section sets in
SERA was only 1%.
This study proved that rAu-197 was less independent of the grouped cross section data and of
the simulation programs than rMn-55. In addition, the uncertainty of the 197Au(n,) cross
sections (<1%) was lower than that of the 55Mn(n,) reaction (<4.5%) in the IRDF-90 library
[55]. As a consequence, rAu-197 is a preferable activation reaction for beam normalisation in
the TPS. The normalisation factor of the FiR(K63) beam model in SERA was found to be the
same, 0.94, with both activation reactions (Figure 9), which indicated that the neutron
spectrum was correct at the normalisation depth of 2.0 cm. The normalisation of the beam
model to the measured rAu-197 gives the link to the reference monitor unit rate fMU Re

. All the
irradiations that are provided according to the dose plan are given in monitor units at the FiR 1
facility.
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5 TREATMENT PLANNING IN NCT
5.1 Principles
The purpose of the BNCT treatment plan is to achieve an optimised geometrical set-up of
neutron fields relative to the patient and the monitor units connected to each field. The
geometrical set-up consists of a selection of numbers, sizes, directions and weights of fields.
The monitor units per field involve a planned radiation dose and a 10B concentration in whole
blood during the irradiation from one field. Optimisation of the treatment plan set-up in the
Finnish clinical protocols is based on the following [13]: 1) a possible flat and high radiation
dose distribution to PTV, 2) an avoidance of the radiation dose in the contralateral hemisphere
and 3) maintaining doses under the pre-set dose maximum in the radiosensitive tissues of a
patient.
A 3D geometrical model of a target is created to compute the radiation doses in the TPS [14,
30]. In the Finnish studies, the construction of the head model has been based on MR images
(Studies VI, VII). The structures from the images are outlined based on either the non-uniform
rational B-Spines (NURBS) technique (in BNCT_Rtpe) [30] or pixel-by-pixel uniform
volume element (univel) reconstruction (in SERA) [61].
The weighted dose in PTV, tumour and normal brain of the patient’s head is calculated from
Equation 2. The prescribed weighted dose DW is given to a patient in monitor units MU (Study
VII)
f
calc
f
W MU
D
D
MU Re
Re


 ,                                                                   (3)
where 

calc
fDRe  is the calculated dose rate at the reference monitor unit rate fMU Re

. MU is a
reading of the 235U fission chamber that measures epithermal and thermal neutrons in the
beam collimator [56].
During irradiation Mn-Al foils are irradiated on a patient’s head and TLD pellets on the head
and body, and after that the detectors are analysed [62]. The 55Mn(n,) reaction rates and the
gamma doses of these in vivo measurements of the head are compared with the corresponding
values in a treatment plan (Study VII). Suitable TLDs and analysing techniques were
examined in Study V. The gamma dose was measured with MCP-7s TLDs, which have a low
thermal neutron sensitivity. Based on the calculated neutron spectrum at the measurement
location, the thermal neutron sensitivity of the MCP-7s detector is reduced (Studies V, VI).
5.2 Dog brain model
To improve patient safety and determine the radiobiological characteristics of the FiR(K63)
beam, single-fraction dose-response studies were carried out on dog brains before clinical
trials. The dose-planning procedure and the uncertainties of the dose plan were examined
without the boron carrier (Study VI). BNCT_Rtpe was used for the dose planning. Irradiations
were monitored with in vivo dosimeters, as recommended in BNCT of brain tumour patients.
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According to the dosimetric study (Study VI), the estimated uncertainties (1 SD) of the
calculated absorbed gamma, nitrogen and fast neutron doses were 9.6%, 5.8% and 36%,
respectively, at the thermal neutron maximum in brain tissue. The uncertainty (1 SD) of the
total absorbed dose from these dose components was 8.9%. The largest source of uncertainty
for the dose components in tissue, based on the measurement uncertainties, was the beam
model. The uncertainty of the gamma dose validated with IC measurements (Study III), in
particular, had a great influence on the uncertainty of the computed total dose in brain tissue
in NCT.
The examination, especially in vivo measurements and their comparison to calculations,
brought out important information about the TPS for clinical trials. The measurement
locations were in the beam entry on the top of the head, between the eyes and in the mouth at
the border of the soft and hard palate and at the level of the oral cavity. At beam entry, the
calculated thermal neutron fluences and the 55Mn(n,) activation reaction rates were
overestimated by 20% as in the phantom studies, which was due to the interpolating
difficulties of the TPS in the air-tissue interface. Near the air cavities, between the eyes and in
the mouth, the computations in the TPS were less accurate. The difference of the calculated
neutron fluence and gamma dose to the measured ones was observed to vary 40-70%. The
uncertainties (1 SD) of the calculation at the measurement point in the mouth were large (37-
65%), which was principally caused the 10 mm uncertainty (1 SD) in a detector location.
However, since the 55Mn(n,) reaction rate mainly from the thermalised neutrons in the head
agreed at the beam entry as in the phantom studies, the thermal neutron fluence (nitrogen
dose) and the induced gamma dose most probably were within the above-mentioned
uncertainties at the thermal neutron maximum. The dose in the thermal neutron maximum (1
cm3), i.e. the peak dose, is usually used as a base to compute the given monitor units [11, 13].
The dosimetry chain of this examination was found to be sufficiently reliable to continue to
clinical trials. The uncertainty of the calculated absorbed total dose without the uncertainty in
the boron concentration at the thermal neutron maximum in brain tissue was below 10%. In
addition, the delivered absorbed dose has metrologically traceable links to the international
dosimetry standards [63]. In connection to the radiobiological characterisation of the beam,
the dose planning of 20 cases, starting from the MR images to the given monitor units,
provided an important foundation for the BNCT dose planning.
5.3 Glioblastoma patients
The first clinical BNCT protocol (P-01) for glioblastoma multiforme (GBM) brain tumour
patients started at the FiR 1 facility in May 1999 [13], and the second protocol (P-03) for
recurrent GBM patients in February 2001. The treatment planning in protocol P-01 was done
with the BNCT_Rtpe program, and in protocol P-03 with the SERA program. Before starting
to use SERA in protocol P-03, the TPS was verified and validated in the phantoms, and ten
BNCT_Rtpe treatment plans of the protocol P-01 were recalculated with SERA [60].
For treatment planning, an individual approximate model of the irradiated target (head of
GBM patient) is created based on transaxial MR images (Study VII). A minimum of three
MRI-visible markers are taped on the skin surface for MR imaging, and the position of the
markers in the MR images of the head model are used for patient positioning [26]. The
computational head model consists of the skin, skull, brain, PTV and tumour region in
protocol P-01. In addition to these structures, the air cavities were also outlined in protocol P-
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03. Since the image data are inadequate to define the individual tissue compositions in BNCT,
the compositions were defined after literature based on the ICRU 46 Report [8] (Study VII).
At the HFR treatment planning of glioma patients in BNCT, the skull of the head was not
modelled separately in the head model [64]. In the FiR(K63) beam, the lack of skull in the
human head model increased the total weighted peak dose rate by 4-5%, and the peak was
transferred by the thickness of skull towards the surface direction. For these reasons, the skull
was required for inclusion in the head model in the BNCT treatment planning. The physical
doses (i.e. fluence-to-kerma) are computed to the adult brain tissue defined by ICRU 46
(Study VII). In contrast with Study VII, the fluence-to-kerma conversions of the weighted
dose components are calculated in the brain tissue using the brain tissue composition (equal
amounts of white and grey matter) defined by Brooks et al. [65]. This tissue composition was
used in the dose determination of the radiobiological studies when the weighting factors of 3.2
for fast neutron and nitrogen doses and of 1.0 for the gamma dose were determined in the
BMRR beam [24] and was applied with the factors in our BNCT dose computations.
The uncertainty of the absorbed peak dose of the brain cancer patient in BNCT in the
FiR(K63) beam can be estimated approximately from the dose uncertainties based on the dog
head model in NCT (Study VI). The chains of the dog brain NCT and the human brain cancer
patient in BNCT starting from the MR images of the dose plan to the irradiation set-up are
analogous. Their major processional difference is the use of the boron carrier in BNCT and its
absence in NCT. In BNCT, so far the boron concentration in tissue is estimated to be
homogeneous in the TPS. The defined 10B concentration in tissue is based on the tissue-to-
whole-blood ratio of the 10B concentration that is estimated from the biological models [24].
The uncertainty of the boron dose is estimated to be equal to the uncertainty of the computed
nitrogen dose of 6% (1SD), since both doses are directly proportional to the thermal neutron
fluence. The uncertainty of the boron dose DB does not include the uncertainty of the boron
concentration in tissue, which is part of future BNCT research world wide. The uncertainty of
the computed gamma dose Dg was estimated to be 10% (1SD), and the uncertainty of the
computed fast neutron dose Dfast_n 36% (1SD) at the thermal neutron maximum in brain tissue
(Study VI). In one hour irradiation, the typical absorbed dose components at the thermal
neutron maximum in normal brain tissue are 5.3 Gy, 5.0 Gy, 0.9 Gy and 0.2 Gy for DB, Dg, DN
and Dfast_n, respectively, at a 12 ppm 10B concentration blood level in a patient (Study VII).
From the dose contributions and dose uncertainties, the uncertainty of the computed absorbed
total dose can be estimated to be 8% (1SD) without uncertainty in boron concentration at the
thermal neutron maximum in the brain tissue of a patient in the FiR(K63) beam. Recently,
Kortesniemi [40] estimated in his Ph.D. thesis a 30% (1 SD) uncertainty in boron
concentration in normal tissue. When taking this boron concentration uncertainty into account,
the uncertainty of the computed absorbed total dose is 20% (1 SD) in the normal brain.
During the irradiation of each field Mn-Al foils are irradiated on a patient’s head and TLD
pellets (MCP-7s) on the head and body, and after treatment the detectors are analysed [62].
The 55Mn(n,) reaction rates and the gamma doses of these in vivo measurements of the head
are compared with the corresponding values in a treatment plan. The value of in vivo
dosimetry in BNCT is to verify the computed doses. The in vivo measurements in the first
protocol (P-01) led to the observation that when including the air cavities in the head model
the calculated neutron dose distribution in the frontal part of the head was markedly enhanced
in the posterior–anterior field (Table 5). However, the more precise head model had no
influence on absorbed dose components at the thermal neutron maximum; nor did it have a
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strong effect on gamma doses (Table 6). Based on these in vivo measurements, the air cavities
of the head should be included in the anatomic model of the patient head in BNCT.
Table 5. Comparison of measured 55Mn(n,) reaction rates rMn-55 with calculated values (C/E)
in two head models of the same patient with and without inclusion of air cavities in the model.
Location Measured rMn-55, 1/s C/E, no air
cavities
C/E, air
cavities
Beam entry point 6.44E-15 1.24 1.17
Beam side ear canal 1.05E-15 0.69 0.81
Between eyes TAT 4.38E-17 0.20 0.51
Table 6. Comparison of measured gamma doses Dg with calculated values (C/E) in two head
models of the same patient with and without inclusion of air cavities in the model.
Location Measured Dg, mGy C/E, no air
cavities
C/E, air
cavities
Beam opposite TAT 200 0.86 0.93
Beam side ear canal 260 1.04 1.00
Between eyes TAT 100 0.93 0.94
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6 DISCUSSION
The 2D cylinder symmetrical horizontal DORT model of the FiR 1 beam was observed to be
an effective and reliable tool for examining the effects of different geometrical structures
(moderator, collimator, shielding) on neutron and photon spectra. The full neutron and photon
spectra in the 47-neutron and 20-photon BUGLE-80 energy groups were achieved in the
whole moderator-collimator part of the model in 60 minutes with a 0.01% flux convergence
criterion in each energy group (SUN Ultra 60 computer). The changes in the beam geometry
were verified primarily with activation measurements, and the corresponding changes in the
DORT model were found to be reliably computed. The previously detected [32, 33, 46] 30-
50% fast neutron underestimation in the aluminium-oxygen moderated epithermal neutron
beam model was not observed in the aluminium-fluorine moderated beam model. Therefore,
no spectral correction to the FiR(K63) beam model was required. The detailed 2D model of
the reactor core, where a similar type of fuel elements was divided into the separate zones and
the graphite reflector density was decreased due to air-filled structures in the beam direction,
appeared to provide a more accurate model.
The Code of Practice for NCT dosimetry is currently under construction [35]. A method to
determine the beam model for the treatment planning of brain cancer patients in NCT was
developed for the FiR(K63) epithermal neutron beam. Suitable brain tissue substitute phantom
materials are required to validate the thermal neutron fluence th, to which the boron DB and
nitrogen doses DN are directly proportional, and the total neutron Dn and total gamma dose Dg
distributions in a situation similar to patient radiation therapy. The parallel verification of the
computed distributions of the dose components in the slightly different brain tissue substitute
phantoms confirmed that the continuous neutron-photon spectra of the beam were correctly
modelled. In the collimated FiR(K63) beam, PMMA was found to simulate th in the brain
tissue 3 percentage units closer than water, which was opposite to the situation in the
uncollimated epithermal neutron beam (Study II). Water simulates Dg in the brain tissue
approximately 10 percentage units closer than PMMA in the uncollimated and the collimated
epithermal neutron beams. PMMA is more suitable for the beam model normalisation to the
activation measurements than water because of its superior ability to simulate th in the brain
tissue. PMMA is also more practical than water in the measurements because the detector
place can be defined more accurately in solid material than in liquid, and detector-supporting
materials, which may disturb the neutron spectrum, are not needed. In the accelerator-based
epithermal neutron beam, A-150 plastic was computed to simulate Dg in the brain tissue 9
percentage units closer than PMMA [66]. At the thermal neutron maximum, i.e. the beam
normalisation point, A-150 and PMMA simulated th in the brain tissue equally, therefore,
both are suitable for beam normalisation.
Activation measurements are the primary measurement technique in NCT since the
uncertainty of rAu-197 and rMn-55 is only 3% (1SD), which is considerably lower than
uncertainties in ionisation chamber measurements (6.3% (1SD) for Dg and 21.5% (1SD) for
Dn, Study III). The use of activation measurements in the experimental validation of the
computations was relevant since the calculated thermal neutron-induced doses in the
FiR(K63) beam were 90-95% of the total dose, from 0.5-cm to 10-cm depth, in a water
phantom. The parallel use of the 197Au(n,) and 55Mn(n,) reactions in the validation of the
computations in a phantom gave more reliability to computed neutron spectra. The measured
and computed activation reaction rates are independent of each other, especially when diluted
foils are used. The very diluted foils are practical to use since their disruption to rAu-197 and
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rMn-55  was negligible (0.2%) due to exceptionally low self-shielding. Therefore, the effect of
the foils in dose calculations was insignificant and was not taken into account. This was
especially important in the validation and normalisation of the beam model and the dose
computations in the phantoms.
The 197Au(n,) activation reaction rate rAu-197 is recommended to normalise the beam model in
a phantom, especially if the epithermal neutron beam has a low fast neutron and beam gamma
contamination. Even thought the 55Mn(n,) reaction produces a greater response (97%) in the
thermal neutrons than the 197Au(n,) reaction (58%) at the thermal neutron maximum in a
PMMA phantom in the FiR(K63) beam, it is less suitable than the latter for normalisation.
The computed rAu-197 was less independent of the energy structure of the activation cross
sections in the TPS than rMn-55. Furthermore, the uncertainties of 197Au(n,) activation cross
sections (< 1%) are lower than the uncertainties of 55Mn(n,) activation cross sections (<4.5%)
[55]. However, if the beam model is correct, the same normalisation factor is achieved with
both activation reactions and no dose component related normalisation coefficients are
needed. Although the neutron spectrum is correctly modelled and normalised, the beam
gamma component might need a separate modification in the model. The future plan is to
verify the beam model gamma spectrum.
The dose computations in the TPS were quite reliable in the homogeneous tissue but have
shortages in the heterogeneous areas near air cavities and in other air-tissue interfaces, where
the point doses are quite uncertain (Study VI). The soft tissues, skull and air cavities need to
be outlined separately to get an accurate 3D head model for treatment planning. Enhanced
reliability in the dose computations can be achieved if the continuous cross section data and
variable sizes of tally voxels are included in TPS. This would particularly reduce the
uncertainty of the calculated doses/activation reaction rates on the skin and near the air
cavities. As a consequence, the validation of the computed doses in a head model with in vivo
measurements becomes even more reasonable.
 
 The main uncertainty of the calculated dose in NCT arises from uncertainties in measurements
used to configure the beam model in a phantom. Therefore, the uncertainty of the computed
doses can be reduced by developing the measurement technique of gamma and fast neutron
doses in a phantom. The uncertainty of the computed BNCT total dose in the head model was
estimated to be 8% at the dose maximum in brain tissue, assuming no error in boron
concentration. This estimation is based on our study of the dog brain model (Study VI). The
different computed dose components have their own (1SD) uncertainties; the fast neutron
dose has the highest uncertainty of 36%, the gamma dose 10% and the nitrogen (boron) dose
6%. The uncertainty of the boron dose does not include the uncertainty of the boron
distribution in tissue. Determination of boron distribution is a major part of future BNCT
research world-wide.
 
The epithermal neutron beam model for TPS was validated for the brain tumour radiation
therapy. Future NCT radiotherapy trials might extend to tumours other than those of the brain.
When extracranial targets are treated with BNCT, the beam model in the TPS will need to be
validated in a large-sized phantom. In this situation, the calculated dose distribution in the
anatomic model should also be verified with in vivo dosimetry to give more reliabilily to the
dose plan.
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7 SUMMARY AND CONCLUSION
The beam model of the epithermal neutron beam is needed for computational dosimetry and
treatment planning since all beams in NCT are individual. The model is validated
experimentally in a situation similar to patient treatment. The thermal neutron fluence is most
important to validate in a phantom since it induces the major portion of the absorbed doses in
tissue. This is emphasised in the validation of the high-quality epithermal neutron beam,
which has very low photon and fast neutron contamination in the beam, similar to the
FiR(K63) beam. However, the total gamma and the total neutron doses in a tissue substitute
phantom should be validated to ensure the reliability of the beam gamma-induced dose and
the fast neutron dose in tissue and the dose computations of the TPS.
Study I describes the cylindrical horizontal DORT model of the FiR 1 epithermal neutron
beam and the experimental validation of the calculated free beam neutron spectrum. The free
beam model agreed well with the measurements in three neutron energy groups and fairly well
with those 47 neutron energy groups. According to these measurements, the actual thermal
neutron fluence was somewhat higher than the calculated fluence. However, upon more
detailed analysis of the measurements, the experimental thermal neutron fluence approached
the calculated values. The beam model was sufficiently accurate to be used in TPS.
Study II computationally examined suitable phantom materials for the NCT dosimetry. Two
brain tissue equivalent liquids were designed from chemical compounds in addition to the
simple materials (PMMA and water). Of the simple materials, water simulated the thermal
neutron fluence and the gamma and fast neutron doses in the brain tissue better than PMMA
in the uncollimated epithermal neutron beam.
The later computations in the collimated epithermal neutron beam FiR(63) showed that
PMMA simulates the thermal neutrons in the brain tissue slightly better than water at the
thermal neutron maximum. Because of this and the practicality of solid material in activation
measurements, PMMA is the recommended material in epithermal neutron beam
normalisation. However, water is superior to PMMA for simulating the absorbed gamma dose
in brain tissue, therefore, the computed gamma dose is recommended for verification in a
water phantom.
The pair ionisation chamber measurement method was developed to determine the total
absorbed gamma dose and the neutron doses in a phantom for the NCT dosimetry in Study
III. The measured and computed gamma and neutron doses agreed within the measurement
uncertainties. The study gave more reliability to the calculated beam gamma and fast neutron
dose distributions in a phantom. The overall uncertainties of the IC measurement technique in
NCT dosimetry render it unsatisfactory as a primary measure of gamma and neutron doses in
a phantom. In the high-quality epithermal neutron beam, the amount of absorbed gamma
depth dose is 80-95% (0-10 cm) of the total dose, thus the 6.3% (1SD) measurement
uncertainty in the gamma dose increases the uncertainty of the computed total dose in NCT
most.
In Study IV the FiR(K63) beam model was defined for the treatment planning system. The
beam model was defined from the DORT model of the FiR(K63) beam for each beam size
separately. Each size was separately normalised at the thermal neutron maximum in the
PMMA phantom with Au activation foil measurement. The 197Au(n,) activation reaction was
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observed to be less uncertain for the epithermal neutron beam normalisation than the
55Mn(n,) reaction. The 197Au(n,) reaction was found to be less independent of the energy
grouping of the cross section data than the 55Mn(n,) reaction in the TPS. The presently used
TPS has drawbacks in the computation of surface dose, which is overestimated by
approximately 10-20%.
Suitable TLDs and their thermal neutron reduction method were studied in Study V. The
MCP-7s detector was observed to be suitable for measurements of the absorbed gamma dose
in NCT. However, the method requires accurate data on the calculated neutron spectrum for
the thermal neutron reduction at the measurement location. The significance of the MCP-7s
detector in NCT is that it can be used in in vivo measurements to verify gamma doses of the
computational model, especially because their small size and wirelessness.
The dose planning procedure and the uncertainties of the epithermal neutron-induced
computed doses were examined in Study VI. The uncertainty of the computed total NCT
doses was 9% at the thermal neutron maximum in the dog head model. During irradiation the
calculated neutron fluences and the absorbed gamma doses were verified on the skin and in
the mouth with in vivo measurements using Mn-Al activation foils and MCP-7s TLDs,
respectively. The examination showed that in the homogeneous area on the top of the head the
calculated doses had an equal overestimation than in a phantom, which predicts that the
calculated dose accuracies were within the measurement uncertainties. However, the accuracy
of the calculated point dose at air-tissue surfaces and near air cavities was insufficient.
Study VII described the chain of BNCT treatment planning for brain tumour patients from
the dosimetric point of view. According to a sample BNCT dose plan, the weighted boron
dose is approximately 90% of the total weighted dose for a tumour and 45% for a normal
brain at the dose maximum. Therefore, experimental validation of the thermal neutron fluence
that is directly proportional to the boron dose is essential in a phantom and in tissue with in
vivo measurements to assure reliability of doses in BNCT.
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